| Characteristic | Funding in million U.S. dollars |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
July 2019
United States
fiscal years 2001 to 2019
* Includes TB funding provided through USAID. Bilateral TB includes funding for the Global TB Drug Facility. Includes base and supplemental funding. FY13 includes the effects of sequestration. FY19 is based on funding provided in the 鈥淐onsolidated Appropriations Act, 2019鈥 (P.L. 116-6) and is a preliminary estimate. Some funding for TB programs provided through the Economic Support Fund (ESF) account at USAID is not yet known for FY19 and the FY20 Request and is assumed to remain at prior year levels. Totals do not include global TB funding provided by the CDC through a transfer from the 鈥淗IV/AIDS, Viral Hepatitis, STI and TB Prevention鈥 account.









